TriangleNCT02467270 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 8.9 years
What was measured
OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.
Analysis population: All randomized participants were included in the analysis.
Groups in this outcome
Treatment Period: Cohort A: Ponatinib 45 mg
Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Treatment Period: Cohort B: Ponatinib 30 mg
Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Treatment Period: Cohort C: Ponatinib 15 mg
Participants received ponatinib 15 mg orally once daily in each 28-day cycle.
| Group | Source count |
|---|---|
| Treatment Period: Cohort A: Ponatinib 45 mg | 94 |
| Treatment Period: Cohort B: Ponatinib 30 mg | 95 |
| Treatment Period: Cohort C: Ponatinib 15 mg | 94 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment Period: Cohort A: Ponatinib 45 mg | NA | Not reported | NA | NA | Median and 95% CI were not available due to censoring. |
| Treatment Period: Cohort B: Ponatinib 30 mg | NA | Not reported | NA | NA | Median and 95% CI were not available due to censoring. |
| Treatment Period: Cohort C: Ponatinib 15 mg | NA | Not reported | NA | NA | Median and 95% CI were not available due to censoring. |
Complete source fields
- classes
- categories
- measurements
- comment
- Median and 95% CI were not available due to censoring.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- Median and 95% CI were not available due to censoring.
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- Median and 95% CI were not available due to censoring.
- group Id
- OG002
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 94
- group Id
- OG001
- value
- 95
- group Id
- OG002
- value
- 94
- units
- Participants
- description
- OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
- id
- OG000
- title
- Treatment Period: Cohort A: Ponatinib 45 mg
- description
- Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
- id
- OG001
- title
- Treatment Period: Cohort B: Ponatinib 30 mg
- description
- Participants received ponatinib 15 mg orally once daily in each 28-day cycle.
- id
- OG002
- title
- Treatment Period: Cohort C: Ponatinib 15 mg
- param Type
- MEDIAN
- population Description
- All randomized participants were included in the analysis.
- reporting Status
- POSTED
- time Frame
- Up to approximately 8.9 years
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice